QNCX
Quince Therapeutics, Inc.NASDAQHealthcare$0.10-3.23%ClosedMarket Cap: $5.5M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.04
P/S
0.00
EV/EBITDA
-0.31
DCF Value
$-0.24
FCF Yield
-707.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-370.5%
ROA
-135.1%
ROIC
-45.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q3 2025 | $0.00 | -Infinity% | $-11.4M | $-13.4M | $-0.25 | — |
| Q2 2025 | $0.00 | -Infinity% | $-9.9M | $-16.0M | $-0.34 | — |
| Q1 2025 | $0.00 | NaN% | $-14.9M | $-15.0M | $-0.34 | — |
| Q4 2024 | $0.00 | -Infinity% | $-10.1M | $-12.5M | $-0.28 | — |
| FY 2024 | $0.00 | NaN% | $-57.3M | $-56.8M | $-1.31 | — |
| Q3 2024 | $0.00 | NaN% | $-5.9M | $-5.5M | $-0.13 | — |
| Q2 2024 | $0.00 | NaN% | $-28.2M | $-27.7M | $-0.64 | — |
| Q1 2024 | $0.00 | NaN% | $-11.2M | $-11.1M | $-0.26 | — |
| Q4 2023 | $0.00 | -Infinity% | $-8.3M | $-8.9M | $-0.22 | — |
| FY 2023 | $0.00 | NaN% | $-34.6M | $-31.4M | $-0.84 | — |
| Q3 2023 | $0.00 | NaN% | $-6.1M | $-5.4M | $-0.15 | — |
| Q2 2023 | $0.00 | NaN% | $-5.6M | $-4.9M | $-0.14 | — |